Clinical Trials in Morgantown West Virginia

Results

Hot

Post your clinical trial on JoinClinicalTrials.com

Ellijay, Georgia 30536
United States

Post your clinical trial on JoinClinicalTrials.com to reach thousands of viewer daily. Our Clinical Trial Listings have consistently proven to be an ...

Results 1 - 1 of 1

Two Year Study With Robotic-Arm Assisted Hip Surgery.
NCT03891199
Conditions: Surgery; Hip Osteoarthritis
Intervention: Procedure: Robotic-Arm Assisted THA
Sponsors: West Virginia University; Stryker Nordic; West Penn Allegheny Health System
Recruiting
Carvedilol With Chemotherapy in Second Line Glioblastoma and Response of Circulating Tumor Cells
NCT03861598
Conditions: Glioblastoma Multiforme; Glioblastoma
Intervention: Drug: Carvedilol
Sponsors: West Virginia University; West Virginia Clinical and Translational Science Institute
Recruiting
Palliative Care Coaching for Families With Rare Advanced Lung Diseases
NCT03813667
Conditions: Lung Diseases; Rare Non-Neoplastic Disorder
Intervention: Behavioral: Intervention FamPALcare
Sponsor: West Virginia University
Recruiting
Use of Tele-Exercise for Translating an Evidence-Based Fall-Prevention Program for Older Adults in West Virginia
NCT03714100
Condition: Accidental Falls
Intervention: Behavioral: Tai Ji Quan: Moving for Better Balance
Sponsor: West Virginia University
Recruiting
A Comparison of NETSPOT Imaging Versus F-FDG-PET in Head and Neck Cancer Patients
NCT03602911
Condition: Head and Neck Squamous Cell Carcinoma
Intervention: Drug: The isotope 68Ga, NETSPOT and 18F-FDG-PET/CT
Sponsor: West Virginia University
Recruiting
Methionine-Restricted Diet to Potentiate The Effects of Radiation Therapy
NCT03574194
Conditions: Cancer; Lung Cancer; Prostate Cancer; Breast Cancer
Intervention: Dietary Supplement: Methionine-restricted diet
Sponsors: West Virginia University; West Virginia Clinical and Translational Science Institute
Recruiting
Use of Sugammadex for Reversal of Paralysis in Microlaryngoscopy
NCT03111121
Conditions: Microlaryngoscopy; Rigid Bronchoscopy
Interventions: Drug: Sugammadex; Drug: neostigmine; Drug: glycopyrrolate
Sponsor: West Virginia University
Recruiting
ExAblate Blood-Brain Barrier (BBB) Disruption for the Treatment of Alzheimer's Disease
NCT03671889
Condition: Alzheimer Disease
Intervention: Device: Blood Brain Barrier (BBB) Disruption
Sponsor: InSightec
Recruiting
Establishing the Recommended Biological Dose for AE37 Peptide Vaccine in Combination With Pembrolizumab That Will Enhance the Tumor-specific Immune Response and Demonstrate Efficacy in Patients With Advanced Triple-negative Breast Cancer
NCT04024800
Condition: Triple-negative Breast Cancer
Interventions: Biological: AE37 Peptide vaccine; Biological: Pembrolizumab
Sponsors: Antigen Express, Inc; Merck Sharp & Dohme Corp.; NSABP Foundation Inc
Recruiting
Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors
NCT03662204
Conditions: Breast Cancer; Lung Cancer; Colorectal Cancer; Prostate Cancer; Bladder Cancer; Uterine Cancer; Kidney Cancer; Renal Pelvis Cancer; Pancreatic Cancer; Liver Cancer; Stomach Cancer; Ovarian Cancer; Esophageal Cancer
Intervention: Other: Blood Sample Collection
Sponsor: Exact Sciences Corporation
Recruiting
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
NCT02465060
Conditions: Advanced Malignant Solid Neoplasm; Bladder Carcinoma; Breast Carcinoma; Cervical Carcinoma; Colon Carcinoma; Colorectal Carcinoma; Endometrial Carcinoma; Esophageal Carcinoma; Gastric Carcinoma; Glioma; Head and Neck Carcinoma; Kidney Carcinoma; Liver and Intrahepatic Bile Duct Carcinoma; Lung Carcinoma; Lymphoma; Malignant Uterine Neoplasm; Melanoma; Ovarian Carcinoma; Pancreatic Carcinoma; Plasma Cell Myeloma; Prostate Carcinoma; Rectal Carcinoma; Recurrent Bladder Carcinoma; Recurrent Breast Carcinoma; Recurrent Cervical Carcinoma; Recurrent Colon Carcinoma; Recurrent Colorectal Carcinoma; Recurrent Esophageal Carcinoma; Recurrent Gastric Carcinoma; Recurrent Glioma; Recurrent Head and Neck Carcinoma; Recurrent Liver Carcinoma; Recurrent Lung Carcinoma; Recurrent Lymphoma; Recurrent Malignant Solid Neoplasm; Recurrent Melanoma; Recurrent Ovarian Carcinoma; Recurrent Pancreatic Carcinoma; Recurrent Plasma Cell Myeloma; Recurrent Prostate Carcinoma; Recurrent Rectal Carcinoma; Recurrent Skin Carcinoma; Recurrent Thyroid Gland Carcinoma; Recurrent Uterine Corpus Carcinoma; Refractory Lymphoma; Refractory Malignant Solid Neoplasm; Refractory Plasma Cell Myeloma; Skin Carcinoma; Thyroid Gland Carcinoma; Uterine Corpus Cancer
Interventions: Drug: Adavosertib; Drug: Afatinib; Drug: Afatinib Dimaleate; Drug: Binimetinib; Drug: Capivasertib; Drug: Copanlisib; Drug: Copanlisib Hydrochloride; Drug: Crizotinib; Other: Cytology Specimen Collection Procedure; Drug: Dabrafenib; Drug: Dabrafenib Mesylate; Drug: Dasatinib; Drug: Defactinib; Drug: Defactinib Hydrochloride; Drug: Erdafitinib; Drug: FGFR Inhibitor AZD4547; Drug: Ipatasertib; Other: Laboratory Biomarker Analysis; Drug: Larotrectinib; Drug: Larotrectinib Sulfate; Biological: Nivolumab; Drug: Osimertinib; Drug: Palbociclib; Biological: Pertuzumab; Drug: PI3K-beta Inhibitor GSK2636771; Drug: Sapanisertib; Drug: Sunitinib Malate; Drug: Taselisib; Drug: Trametinib; Biological: Trastuzumab; Biological: Trastuzumab Emtansine; Drug: Ulixertinib; Drug: Vismodegib
Sponsor: National Cancer Institute (NCI)
Recruiting
A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated Mantle Cell Lymphoma
NCT02972840
Condition: Lymphoma, Mantle Cell
Interventions: Drug: Acalabrutinib in combination with bendamustine and rituximab; Drug: Placebo in combination with bendamustine and rituximab
Sponsor: Acerta Pharma BV
Recruiting
Longitudinal Performance of Epi proColon
NCT03218423
Conditions: Colorectal Cancer; Colorectal Neoplasms
Intervention: Device: Epi proColon
Sponsor: Epigenomics, Inc
Recruiting
Clinical Trial of BP1001(Liposomal Grb2 Antisense Oligonucleotide) in Combination With Decitabine in AML / High Risk MDS
NCT02781883
Conditions: Acute Myeloid Leukemia (AML); High-risk Myelodysplastic Syndrome
Intervention: Drug: BP1001 in combination with decitabine
Sponsor: Bio-Path Holdings, Inc.
Recruiting
Long-term Safety and Efficacy Extension Trial of Bimatoprost SR
NCT03891446
Conditions: Open-Angle Glaucoma; Ocular Hypertension
Intervention: Drug: Bimatoprost SR
Sponsor: Allergan
Recruiting
A Study of RO7082859 in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Non-Hodgkin Lymphomas
NCT03467373
Conditions: B-Cell Lymphoma; Non-Hodgkin Lymphoma
Interventions: Drug: RO7082859; Drug: Obinutuzumab (G); Drug: Rituximab (R); Drug: Tocilizumab; Drug: Cyclophosphamide; Drug: Doxorubicin; Drug: Vincristine; Drug: Prednisone
Sponsor: Hoffmann-La Roche
Recruiting
Efficacy and Safety of EXPAREL Versus Standard of Care (SoC) in Subjects Undergoing Elective Cesarean Section
NCT03853694
Conditions: Elective Cesarean Section; Pain Management
Interventions: Drug: 50 mcg Duramorph+ EXPAREL + multi-modal pain regimen; Drug: 150 mcg Duramorph + multi-modal pain regimen; Drug: Exparel TAP + multi-modal pain regimen
Sponsor: Pacira Pharmaceuticals, Inc
Recruiting
Durvalumab vs Placebo Following Stereotactic Body Radiation Therapy in Early Stage Non-small Cell Lung Cancer Patients
NCT03833154
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: Durvalumab; Other: Placebo
Sponsor: AstraZeneca
Recruiting
Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLC
NCT03822351
Conditions: Stage III Non-small Cell Lung Cancer; Unresectable
Interventions: Drug: Durvalumab + Oleclumab; Drug: Durvalumab; Drug: Durvalumab + Monalizumab
Sponsor: MedImmune LLC
Recruiting
A Disease Registry of Patients With Mantle Cell Lymphoma
NCT03816683
Condition: Mantle Cell Lymphoma
Intervention:
Sponsor: AstraZeneca
Recruiting
Sleep for Stroke Management and Recovery Trial
NCT03812653
Conditions: Ischemic Stroke; Sleep Apnea; Sleep Apnea, Obstructive; TIA; Stroke; CPAP; Telemedicine; Home Sleep Apnea Test; Randomized Clinical Trial; Multicenter Trial
Intervention: Device: CPAP
Sponsors: University of Michigan; National Institute of Neurological Disorders and Stroke (NINDS); FusionHealth LLC; Medical University of South Carolina; University of Cincinnati
Recruiting
Accelerated Hypofractionated or Conventionally Fractionated Radiotherapy and Durvalumab in Treating Patients With Stage II-III Non-small Cell Lung Cancer
NCT03801902
Conditions: Lung Non-Small Cell Carcinoma; PD-L1 Overexpression; Recurrent Lung Carcinoma; Stage II Lung Cancer AJCC v8; Stage IIA Lung Cancer AJCC v8; Stage IIB Lung Cancer AJCC v8; Stage III Lung Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8; Stage IIIB Lung Cancer AJCC v8; Stage IIIC Lung Cancer AJCC v8
Interventions: Biological: Durvalumab; Radiation: Fractionated Stereotactic Radiation Therapy; Radiation: Hypofractionated Radiation Therapy
Sponsor: National Cancer Institute (NCI)
Recruiting
A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer
NCT03800134
Condition: Non-Small Cell Lung Cancer
Interventions: Drug: Durvalumab; Other: Placebo; Drug: Carboplatin/Paclitaxel; Drug: Cisplatin/Gemcitabine; Drug: Pemetrexed/Cisplatin; Drug: Pemetrexed/Carboplatin
Sponsor: AstraZeneca
Recruiting
Diabetic Gastroparesis Study 05
NCT03786380
Condition: Gastroparesis
Intervention: Drug: Relamorelin 10 μg
Sponsor: Allergan
Recruiting
A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Relapsing Forms of Multiple Sclerosis
NCT03737851
Condition: Multiple Sclerosis (MS)
Interventions: Drug: elezanumab; Drug: placebo
Sponsor: AbbVie
Recruiting
A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Progressive Forms of Multiple Sclerosis
NCT03737812
Condition: Multiple Sclerosis (MS)
Interventions: Drug: elezanumab; Drug: placebo
Sponsor: AbbVie
Recruiting
AtriCure CryoICE Lesions for Persistent and Long-standing Persistent Atrial Fibrillation Treatment
NCT03732794
Conditions: Atrial Fibrillation; Persistent Atrial Fibrillation; Longstanding Persistent Atrial Fibrillation
Intervention: Device: AtriCure CryoICE & AtriClip LAA Exclusion
Sponsor: AtriCure, Inc.
Recruiting
Treatment of Pain Associated With Lumbosacral Radiculopathy in Adults
NCT03727100
Condition: Lumbosacral Radiculopathy
Interventions: Combination Product: Clonidine Micropellets; Other: Sham
Sponsors: Sollis Therapeutics, Inc.; Lotus Clinical Research, LLC
Recruiting
Apremilast as a Direct Treatment for Mild-to-moderate Plaque Psoriasis Versus Placebo: an Analysis of Clinical Safety and Efficacy
NCT03721172
Condition: Psoriasis
Interventions: Drug: Apremilast; Other: Placebo
Sponsor: Celgene
Recruiting
Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy
NCT03720470
Conditions: Dermatitis; Dermatitis, Atopic; Eczema; Skin Diseases; Skin Diseases, Genetic; Genetic Diseases, Inborn; Skin Diseases, Eczematous; Hypersensitivity; Hypersensitivity, Immediate; Immune System Diseases
Interventions: Drug: PF-04965842 100 mg; Drug: PF-04965842 200 mg; Drug: Dupilumab; Drug: Oral Placebo; Drug: Injectable Placebo
Sponsor: Pfizer
Recruiting
Codex: Study of Inodiftagene Vixteplasmid (BC-819) in Unresponsive NMIBC
NCT03719300
Condition: Non-muscle Invasive Bladder Cancer (NMIBC)
Intervention: Drug: inodiftagene vixteplasmid
Sponsor: Anchiano Therapeutics Israel Ltd.
Recruiting
Non-invasive Vagus Nerve Stimulation for the Prevention of Migraines
NCT03716505
Condition: Migraine Disorders
Interventions: Device: gammaCore Sapphire active; Device: gammaCore Sapphire Sham
Sponsor: ElectroCore INC
Recruiting
LUMINA Phase III Study Assessing the Efficacy and Safety of Intravitreal Injections of 440 ug DE-109 Sirolimus for the Treatment of Active, Non-Infectious Uveitis of the Posterior Segment of the Eye
NCT03711929
Condition: Non Infectious Uveitis
Interventions: Drug: DE-109 Intravitreal Injections; Other: Sham Procedure
Sponsor: Santen Inc.
Recruiting
Phase 3 Study of OTO-104 in Subjects With Unilateral Meniere's Disease
NCT03664674
Condition: Meniere Disease
Interventions: Drug: OTO-104; Drug: Placebo
Sponsor: Otonomy, Inc.
Recruiting
A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma - (FIGHT-302)
NCT03656536
Conditions: Unresectable Cholangiocarcinoma; Metastatic Cholangiocarcinoma
Interventions: Drug: Pemigatinib; Drug: Gemcitabine; Drug: Cisplatin
Sponsor: Incyte Corporation
Recruiting
Biological and Clinical Effects of Palbociclib With Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Breast Cancer
NCT03628066
Condition: Breast Cancer
Interventions: Drug: Letrozole; Drug: Palbociclib; Drug: Goserelin; Diagnostic Test: Oncotype DX Breast Recurrence Score
Sponsors: NSABP Foundation Inc; Genomic Health®, Inc.; Pfizer
Recruiting
A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema (YOSEMITE)
NCT03622580
Condition: Diabetic Macular Edema
Interventions: Drug: Aflibercept; Drug: Faricimab; Drug: Sham Procedure
Sponsor: Hoffmann-La Roche
Recruiting
Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure.
NCT03619213
Condition: Heart Failure With Preserved Ejection Fraction
Interventions: Drug: Dapagliflozin; Drug: Placebo
Sponsor: AstraZeneca
Recruiting
An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo and a Currently Available Treatment in Participants With Moderate-to-Severe Plaque Psoriasis
NCT03611751
Condition: Psoriasis
Interventions: Drug: BMS-986165; Other: Placebo; Drug: Apremilast
Sponsor: Bristol-Myers Squibb
Recruiting
Comparative Study to Evaluate the Efficacy and Safety of MYL-1701P and Eylea® in Subjects With Diabetic Macular Edema
NCT03610646
Condition: Diabetic Macular Edema
Interventions: Drug: MYL-1701P; Drug: Eylea
Sponsors: Mylan Inc.; Momenta Pharmaceuticals, Inc.
Recruiting
Gemcitabine Hydrochloride and Cisplatin in Treating Participants With Invasive Bladder Urothelial Cancer
NCT03609216
Conditions: Infiltrating Bladder Urothelial Carcinoma; Stage II Bladder Urothelial Carcinoma; Stage III Bladder Urothelial Carcinoma
Interventions: Drug: Gemcitabine Hydrochloride; Drug: Cisplatin; Biological: Pegfilgrastim; Procedure: Conventional Surgery; Procedure: Radical Cystectomy; Other: Chemoradiotherapy
Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI)
Recruiting
SI-6603 (Condoliase) Study for Lumbar Disc Herniation
NCT03607838
Condition: Lumbar Disc Herniation
Interventions: Drug: SI-6603; Drug: Sham injection
Sponsor: Seikagaku Corporation
Recruiting
A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma
NCT03599713
Condition: Metastatic Merkel Cell Carcinoma
Intervention: Drug: INCMGA00012
Sponsor: Incyte Corporation
Recruiting
Long-term Extension Trial in Subjects With Atopic Dermatitis Who Participated in Previous Tralokinumab Trials - ECZTEND
NCT03587805
Condition: Atopic Dermatitis
Intervention: Drug: Tralokinumab
Sponsor: LEO Pharma
Recruiting
DEF-314 Better Accuracy in EF Assessment With DEFINITY
NCT03571672
Condition: Cardiac Disease
Intervention: Drug: DEFINITY
Sponsors: Lantheus Medical Imaging; Syneos Health
Recruiting
Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurigo Nodularis
NCT03546816
Conditions: Pruritus; Prurigo Nodularis
Interventions: Drug: 5mg Serlopitant Tablets; Drug: Placebo Tablets
Sponsor: Menlo Therapeutics Inc.
Recruiting
Effect of Sotagliflozin on Cardiovascular Events in Patients With Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF Trial)
NCT03521934
Condition: Heart Failure-Type 2 Diabetes Mellitus
Interventions: Drug: Sotagliflozin (SAR439954); Drug: Placebo
Sponsor: Sanofi
Recruiting
S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis
NCT03499808
Conditions: Amorphous, Eosinophilic, and Acellular Deposit; Constipation; Diarrhea; Early Satiety; Gastrointestinal Hemorrhage; Hepatomegaly; Lymphadenopathy; Macroglossia; Nausea; Primary Systemic Amyloidosis; Purpura; Recurrent Primary Amyloidosis; Refractory Primary Amyloidosis
Interventions: Biological: Isatuximab; Other: Laboratory Biomarker Analysis
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting
A Study of IMO-2125 in Combination With Ipilimumab Versus Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma (ILLUMINATE-301)
NCT03445533
Condition: Metastatic Melanoma
Interventions: Drug: Ipilimumab; Drug: IMO-2125
Sponsors: Idera Pharmaceuticals, Inc.; Bristol-Myers Squibb
Recruiting
Efficacy and Safety of BST-236 in Newly Diagnosed Acute Myeloid Leukemia Patients, Unfit for Standard Induction Therapy
NCT03435848
Condition: Acute Myeloid Leukemia
Intervention: Drug: BST-236
Sponsor: BioSight Ltd.
Recruiting
Clinical Trial to Evaluate the Safety and Effectiveness of Using the Tendyne Mitral Valve System for the Treatment of Symptomatic Mitral Regurgitation
NCT03433274
Conditions: Mitral Regurgitation; Mitral Insufficiency; Mitral Valve Insufficiency; Cardiovascular Diseases; Valve Disease, Heart; Heart Valve Diseases; Functional Mitral Regurgitation; Degenerative Mitral Valve Disease
Interventions: Device: Tendyne Mitral Valve System; Device: MitraClip System
Sponsor: Tendyne Holdings, Inc.
Recruiting
A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 04
NCT03383146
Conditions: Gastroparesis; Diabetes Mellitus
Interventions: Drug: Relamorelin; Drug: Placebo
Sponsor: Allergan
Recruiting
A Study to Quantify Use of Anticoagulation to Improve Management of Atrial Fibrillation
NCT03382613
Condition: Atrial Fibrillation
Intervention:
Sponsor: Janssen Scientific Affairs, LLC
Recruiting
Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3)
NCT03377491
Condition: Pancreas Adenocarcinoma
Interventions: Device: NovoTTF-100L(P); Drug: Gemcitabine; Drug: nab paclitaxel
Sponsor: NovoCure Ltd.
Recruiting
BIOMARKER TRIAL of APALUTAMIDE and RADIATION for RECURRENT PROSTATE CANCER
NCT03371719
Conditions: PSA Progression; Stage III Prostate Adenocarcinoma; Stage IV Prostate Adenocarcinoma
Interventions: Drug: Apalutamide; Radiation: External Beam Radiation Therapy; Other: Placebo
Sponsors: NRG Oncology; National Cancer Institute (NCI)
Recruiting
Stereotactic Body Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Stage IIA-B Prostate Cancer
NCT03367702
Condition: Stage II Prostate Adenocarcinoma
Interventions: Radiation: Intensity-Modulated Radiation Therapy (IMRT); Radiation: Stereotactic Body Radiation Therapy (SBRT)
Sponsors: NRG Oncology; National Cancer Institute (NCI)
Recruiting
An International Study to Evaluate Diagnostic Efficacy of Flurpiridaz (18F) Injection PET MPI in the Detection of Coronary Artery Disease (CAD)
NCT03354273
Condition: Coronary Artery Disease (CAD)
Interventions: Drug: PET MPI; Drug: SPECT MPI; Drug: Pharmacological stress agents
Sponsors: GE Healthcare; Pharmaceutical Product Development, LLC
Recruiting
A Study to Test if Fremanezumab Reduces Headache in Patients With Posttraumatic Headache (PTH)
NCT03347188
Condition: Post-Traumatic Headache
Interventions: Drug: Fremanezumab; Drug: Placebo
Sponsor: Teva Branded Pharmaceutical Products, R&D Inc.
Recruiting
A Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma
NCT03323151
Condition: Mantle-Cell Lymphoma
Interventions: Drug: Ixazomib; Drug: Ibrutinib
Sponsors: PrECOG, LLC.; Takeda
Recruiting
Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
NCT03298451
Condition: Hepatocellular Carcinoma
Interventions: Drug: Durvalumab; Drug: Tremelimumab (Regimen 1); Drug: Tremelimumab (Regimen 2); Drug: Sorafenib; Drug: Durvalumab (Regimen 1); Drug: Durvalumab (Regimen 2)
Sponsor: AstraZeneca
Recruiting
A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis
NCT03285308
Conditions: Gastroparesis; Diabetes Mellitus
Interventions: Drug: Relamorelin; Drug: Placebo
Sponsor: Allergan
Recruiting
Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo
NCT03281954
Condition: Triple Negative Breast Cancer
Interventions: Drug: Placebo; Drug: Atezolizumab
Sponsors: NSABP Foundation Inc; Genentech, Inc.; Hoffmann-La Roche
Recruiting
Palbociclib in Real World Practice
NCT03280303
Conditions: Advanced Breast Cancer; Metastatic Breast Cancer
Intervention: Other: non-interventional
Sponsor: Pfizer
Recruiting
A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma
NCT03274492
Condition: Diffuse Large B-Cell Lymphoma
Interventions: Drug: Polatuzumab Vedotin; Drug: Rituximab; Drug: Cyclophosphamide; Drug: Doxorubicin; Drug: Vincristine; Drug: Vincristine Placebo; Drug: Prednisone; Drug: Polatuzumab vedotin Placebo
Sponsor: Hoffmann-La Roche
Recruiting
Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin
NCT03258554
Conditions: Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Head and Neck Squamous Cell Carcinoma; Hypopharyngeal Squamous Cell Carcinoma; Laryngeal Squamous Cell Carcinoma; Oral Cavity Squamous Cell Carcinoma; Oropharyngeal Squamous Cell Carcinoma; Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Squamous Cell Carcinoma of Unknown Primary; Stage III Hypopharyngeal Carcinoma AJCC v8; Stage III Laryngeal Cancer AJCC v8; Stage III Lip and Oral Cavity Cancer AJCC v8; Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8; Stage IVA Hypopharyngeal Carcinoma AJCC v8; Stage IVA Laryngeal Cancer AJCC v8; Stage IVA Lip and Oral Cavity Cancer AJCC v8; Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8; Stage IVB Hypopharyngeal Carcinoma AJCC v8; Stage IVB Laryngeal Cancer AJCC v8; Stage IVB Lip and Oral Cavity Cancer AJCC v8; Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Interventions: Biological: Cetuximab; Biological: Durvalumab; Radiation: Intensity-Modulated Radiation Therapy; Other: Laboratory Biomarker Analysis; Other: Quality-of-Life Assessment; Other: Questionnaire Administration
Sponsors: National Cancer Institute (NCI); Canadian Cancer Trials Group; NRG Oncology
Recruiting
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
NCT03233711
Conditions: Anal Basaloid Carcinoma; Anal Canal Cloacogenic Carcinoma; Anal Margin Squamous Cell Carcinoma; Stage IIB Anal Cancer AJCC v8; Stage IIIA Anal Cancer AJCC v8; Stage IIIB Anal Cancer AJCC v8; Stage IIIC Anal Cancer AJCC v8
Interventions: Biological: Nivolumab; Other: Patient Observation
Sponsors: National Cancer Institute (NCI); Canadian Cancer Trials Group
Recruiting
Thoracolumbar Burst Fractures Study Comparing Surgical Versus Non-surgical Treatment
NCT02827214
Condition: Thoracolumbar Burst Fracture
Intervention:
Sponsors: AO Clinical Investigation and Documentation; AOSpine International
Recruiting
Heart Sounds Registry
NCT03203629
Condition: Heart Failure; With Decompensation
Intervention: Device: Wearable Cardioverter Defibrillator (WCD)
Sponsor: Zoll Medical Corporation
Recruiting
AtRial Cardiopathy and Antithrombotic Drugs In Prevention After Cryptogenic Stroke
NCT03192215
Condition: Stroke
Interventions: Drug: Apixaban; Drug: Aspirin
Sponsors: Columbia University; National Institute of Neurological Disorders and Stroke (NINDS); University of Cincinnati; Medical University of South Carolina; Bristol-Myers Squibb; Pfizer; Roche Pharma AG; Weill Medical College of Cornell University; University of Washington
Recruiting
A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin
NCT03143153
Condition: Various Advanced Cancer
Interventions: Biological: Nivolumab; Biological: Ipilimumab; Drug: Cisplatin; Drug: Fluorouracil
Sponsors: Bristol-Myers Squibb; Ono Pharmaceutical Co. Ltd
Recruiting
Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer
NCT03137771
Conditions: Recurrent Non-Small Cell Lung Carcinoma; Stage IV Non-Small Cell Lung Cancer
Interventions: Radiation: 3-Dimensional Conformal Radiation Therapy (3D-CRT); Drug: Docetaxel; Drug: Gemcitabine; Radiation: Intensity-Modulated Radiation Therapy (IMRT); Drug: Pemetrexed Disodium; Radiation: Stereotactic Body Radiation Therapy (SBRT); Drug: Erlotinib Hydrochloride; Drug: Pembrolizumab
Sponsors: NRG Oncology; National Cancer Institute (NCI)
Recruiting
A Study of the Efficacy and Safety of Risankizumab in Subjects With Crohn's Disease Who Responded to Induction Treatment in M16-006 or M15-991; or Completed M15-989
NCT03105102
Condition: Crohn's Disease
Interventions: Drug: placebo for risankizumab SC; Drug: risankizumab IV; Drug: placebo for risankizumab IV; Drug: risankizumab SC
Sponsor: AbbVie
Recruiting
Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery
NCT03070886
Conditions: Stage I Prostate Adenocarcinoma; Stage II Prostate Adenocarcinoma; Stage III Prostate Adenocarcinoma
Interventions: Drug: Bicalutamide; Drug: Docetaxel; Radiation: External Beam Radiation Therapy; Drug: Flutamide; Drug: Goserelin Acetate; Other: Laboratory Biomarker Analysis; Drug: Leuprolide Acetate; Drug: Nilutamide
Sponsors: NRG Oncology; National Cancer Institute (NCI)
Recruiting
Study of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Heart Failure With Preserved Ejection Fraction (HFpEF)
NCT03043651
Condition: Pulmonary Hypertension Associated With HFpEF
Intervention: Drug: Oral Treprostinil
Sponsor: United Therapeutics
Recruiting
Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction
NCT03037580
Conditions: Pulmonary Hypertension; Heart Failure With a Preserved Ejection Fraction
Interventions: Drug: Oral treprostinil; Drug: Placebo
Sponsor: United Therapeutics
Recruiting
Ipilimumab With or Without Nivolumab in Treating Patients With Melanoma That Is Stage IV or Stage III and Cannot Be Removed by Surgery
NCT03033576
Conditions: Advanced Melanoma; Melanoma of Unknown Primary; Mucosal Melanoma; Refractory Melanoma; Stage III Cutaneous Melanoma AJCC v7; Stage IIIA Cutaneous Melanoma AJCC v7; Stage IIIB Cutaneous Melanoma AJCC v7; Stage IIIC Cutaneous Melanoma AJCC v7; Stage IV Cutaneous Melanoma AJCC v6 and v7; Unresectable Cutaneous Melanoma; Unresectable Melanoma
Interventions: Biological: Ipilimumab; Biological: Nivolumab
Sponsor: National Cancer Institute (NCI)
Recruiting
A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU)
NCT03033511
Condition: Small Cell Lung Cancer
Interventions: Drug: Placebo for dexamethasone; Drug: Placebo for rovalpituzumab tesirine; Drug: Rovalpituzumab tesirine; Drug: Dexamethasone
Sponsor: AbbVie
Recruiting
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
NCT02997228
Conditions: Colorectal Adenocarcinoma; Mismatch Repair Deficiency; Stage IV Colorectal Cancer AJCC v7; Stage IVA Colorectal Cancer AJCC v7; Stage IVB Colorectal Cancer AJCC v7
Interventions: Drug: Atezolizumab; Biological: Bevacizumab; Drug: Fluorouracil; Drug: Leucovorin Calcium; Drug: Oxaliplatin; Other: Quality-of-Life Assessment; Other: Questionnaire Administration
Sponsors: National Cancer Institute (NCI); NRG Oncology
Recruiting
A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML)
NCT02997202
Condition: Acute Myeloid Leukemia
Interventions: Drug: gilteritinib; Drug: Placebo
Sponsors: Astellas Pharma Global Development, Inc.; National Heart, Lung, and Blood Institute (NHLBI); Blood and Marrow Transplant Clinical Trials Network
Recruiting
Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma
NCT02947347
Condition: Treatment Naive Follicular Lymphoma
Interventions: Drug: ibrutinib; Drug: placebo to match ibrutinib; Drug: rituximab
Sponsor: Pharmacyclics LLC.
Recruiting
Aspirin in Preventing Recurrence of Cancer in Patients With HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation Therapy
NCT02927249
Condition: Node Positive HER2 Negative Breast Cancer
Interventions: Other: Placebo; Drug: Aspirin
Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI); United States Department of Defense; Bayer; Canadian Cancer Trials Group
Recruiting
Veliparib, Pembrolizumab, and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer
NCT02921256
Conditions: Rectal Adenocarcinoma; Stage II Rectal Cancer AJCC v7; Stage III Rectal Cancer AJCC v7
Interventions: Drug: Capecitabine; Drug: Fluorouracil; Radiation: Intensity-Modulated Radiation Therapy; Drug: Leucovorin Calcium; Drug: Oxaliplatin; Biological: Pembrolizumab; Drug: Veliparib
Sponsor: National Cancer Institute (NCI)
Recruiting
Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
NCT02912559
Conditions: Colon Adenocarcinoma; DNA Repair Disorder; Lynch Syndrome; Stage III Colon Cancer AJCC v7; Stage IIIA Colon Cancer AJCC v7; Stage IIIB Colon Cancer AJCC v7; Stage IIIC Colon Cancer AJCC v7
Interventions: Drug: Atezolizumab; Drug: Fluorouracil; Other: Laboratory Biomarker Analysis; Drug: Leucovorin Calcium; Drug: Oxaliplatin; Other: Quality-of-Life Assessment
Sponsor: National Cancer Institute (NCI)
Recruiting
Study Evaluating CERAMENT™|G in Open Diaphyseal Tibial Fractures
NCT02820363
Condition: Tibial Fracture
Interventions: Device: CERAMENT|G; Procedure: SOC treatment
Sponsor: BONESUPPORT AB
Recruiting
RelayPro Thoracic Stent-Graft in Subjects With Thoracic Aortic Aneurysms and Penetrating Atherosclerotic Ulcers
NCT02818972
Condition: Aortic Aneurysm, Thoracic
Intervention: Device: RelayPro
Sponsor: Bolton Medical
Recruiting
Comparative Effectiveness of Pulmonary Embolism Prevention After Hip and Knee Replacement
NCT02810704
Conditions: Pulmonary Embolism; Venous Thrombosis
Interventions: Drug: Enteric Coated Aspirin; Drug: Warfarin; Drug: Rivaroxaban
Sponsors: Medical University of South Carolina; Patient-Centered Outcomes Research Institute; University of Maryland, College Park; Brigham and Women's Hospital; Northwestern University Feinberg School of Medicine
Recruiting
Standardized Treatment of Pulmonary Exacerbations II
NCT02781610
Condition: Pulmonary Cystic Fibrosis
Intervention: Drug: Standard of care IV antibiotic(s)
Sponsors: Chris Goss; Cystic Fibrosis Foundation; CF Therapeutics Development Network Coordinating Center; Medical University of South Carolina; University of Washington
Recruiting
Breast Cancer WEight Loss Study (BWEL Study)
NCT02750826
Condition: Breast Carcinoma
Interventions: Other: Health Education Program; Other: Weight Loss Intervention
Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI); Division of Cancer Control; NIH Biomarker, Imaging and Quality of Life Studies Funding Program (BIQSFP); Canadian Cancer Trials Group
Recruiting
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors
NCT02715284
Condition: Advanced or Metastatic Solid Tumors
Intervention: Biological: TSR-042
Sponsor: Tesaro, Inc.
Recruiting
Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML)
NCT02668653
Conditions: Acute Myeloid Leukemia; Leukemia
Interventions: Drug: Chemotherapy; Drug: Quizartinib; Drug: Placebo
Sponsor: Daiichi Sankyo, Inc.
Recruiting
Panobinostat/Bortezomib/Dexamethasone in Relapsed or Relapsed-and-refractory Multiple Myeloma
NCT02654990
Condition: Multiple Myeloma
Interventions: Drug: panobinostat capsules; Drug: bortezomib injection; Drug: dexamethasone tablets
Sponsor: Novartis Pharmaceuticals
Recruiting
Whole-Brain Radiation Therapy With or Without Hippocampal Avoidance in Treating Patients With Limited Stage or Extensive Stage Small Cell Lung Cancer
NCT02635009
Conditions: Extensive Stage Small Cell Lung Carcinoma; Limited Stage Small Cell Lung Carcinoma
Interventions: Radiation: 3-Dimensional Conformal Radiation Therapy; Other: Cognitive Assessment; Radiation: Intensity-Modulated Radiation Therapy; Other: Laboratory Biomarker Analysis; Other: Quality-of-Life Assessment
Sponsors: NRG Oncology; National Cancer Institute (NCI); Radiation Therapy Oncology Group
Recruiting
Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)
NCT02595944
Conditions: Stage IB Lung Non-Small Cell Carcinoma AJCC v7; Stage II Lung Non-Small Cell Cancer AJCC v7; Stage IIA Lung Non-Small Cell Carcinoma AJCC v7; Stage IIB Lung Non-Small Cell Carcinoma AJCC v7; Stage IIIA Lung Non-Small Cell Cancer AJCC v7
Intervention: Biological: Nivolumab
Sponsor: National Cancer Institute (NCI)
Recruiting
An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation
NCT02577406
Conditions: Leukemia, Myeloid; Isocitrate Dehydrogenase
Interventions: Drug: AG-221; Other: BSC; Drug: Azacitidine; Drug: Low-dose cytarabine (LDAC); Drug: Intermediate-dose cytarabine (IDAC)
Sponsor: Celgene
Recruiting
Comparison of Bimatoprost SR to Selective Laser Trabeculoplasty in Patients With Open-Angle Glaucoma or Ocular Hypertension
NCT02507687
Conditions: Glaucoma, Open-Angle; Ocular Hypertension
Interventions: Drug: Bimatoprost SR; Drug: Sham Bimatoprost SR; Procedure: Selective Laser Trabeculoplasty; Procedure: Sham Selective Laser Trabeculoplasty
Sponsor: Allergan
Recruiting
Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT02502266
Conditions: Deleterious BRCA1 Gene Mutation; Deleterious BRCA2 Gene Mutation; Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Fallopian Tube Undifferentiated Carcinoma; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Seromucinous Carcinoma; Ovarian Serous Adenocarcinoma; Ovarian Transitional Cell Carcinoma; Ovarian Undifferentiated Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma
Interventions: Drug: Cediranib; Drug: Cediranib Maleate; Other: Laboratory Biomarker Analysis; Drug: Olaparib; Drug: Paclitaxel; Drug: Pegylated Liposomal Doxorubicin Hydrochloride; Other: Questionnaire Administration; Drug: Topotecan; Drug: Topotecan Hydrochloride
Sponsors: National Cancer Institute (NCI); NRG Oncology
Recruiting
RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)
NCT02489903
Conditions: Small Cell Carcinoma; Carcinoma, Non-Small-Cell Lung; Neuroendocrine Tumors; Ovarian Epithelial Cancer
Interventions: Drug: RRx-001; Drug: Cisplatin; Drug: Etoposide; Drug: Carboplatin; Drug: Irinotecan; Drug: Vinorelbine; Drug: Doxil; Drug: Gemcitabine; Drug: Taxane; Drug: Paclitaxel; Drug: Nab-Paclitaxel; Drug: Pemetrexed
Sponsor: EpicentRx, Inc.
Recruiting
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer
NCT02488967
Conditions: Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma
Interventions: Drug: Carboplatin; Drug: Cyclophosphamide; Drug: Doxorubicin Hydrochloride; Other: Laboratory Biomarker Analysis; Drug: Paclitaxel
Sponsors: NRG Oncology; National Cancer Institute (NCI)
Recruiting
Radiation Therapy and Cisplatin With or Without Triapine in Treating Patients With Newly Diagnosed Stage IB2, II, or IIIB-IVA Cervical Cancer or Stage II-IVA Vaginal Cancer
NCT02466971
Conditions: Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma, Not Otherwise Specified; Stage IB2 Cervical Cancer AJCC v6 and v7; Stage II Cervical Cancer AJCC v7; Stage II Vaginal Cancer AJCC v6 and v7; Stage IIA Cervical Cancer AJCC v7; Stage IIB Cervical Cancer AJCC v6 and v7; Stage III Vaginal Cancer AJCC v6 and v7; Stage IIIB Cervical Cancer AJCC v6 and v7; Stage IVA Cervical Cancer AJCC v6 and v7; Stage IVA Vaginal Cancer AJCC v6 and v7; Vaginal Adenocarcinoma; Vaginal Adenosquamous Carcinoma; Vaginal Squamous Cell Carcinoma, Not Otherwise Specified
Interventions: Drug: Cisplatin; Radiation: External Beam Radiation Therapy; Radiation: Intensity-Modulated Radiation Therapy; Radiation: Internal Radiation Therapy; Other: Laboratory Biomarker Analysis; Radiation: Radiation Therapy; Drug: Triapine
Sponsors: National Cancer Institute (NCI); NRG Oncology
Recruiting
Standard of Care Therapy With or Without Stereotactic Radiosurgery and/or Surgery in Treating Patients With Limited Metastatic Breast Cancer
NCT02364557
Conditions: Dyspnea; Fatigue; Nausea and Vomiting; Pain; Stage IV Breast Cancer
Interventions: Radiation: Stereotactic Radiosurgery; Procedure: Therapeutic Conventional Surgery; Other: Laboratory Biomarker Analysis
Sponsors: NRG Oncology; National Cancer Institute (NCI)
Recruiting
Expanded Clinical Study of the Tendyne Mitral Valve System
NCT02321514
Condition: Mitral Valve Regurgitation
Intervention: Device: Tendyne Mitral Valve System
Sponsor: Tendyne Holdings, Inc.
Recruiting
A Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast Cancer
NCT02236000
Condition: Breast Cancer
Interventions: Drug: Neratinib; Drug: T-DM1
Sponsors: NSABP Foundation Inc; Puma Biotechnology, Inc.
Recruiting
Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma
NCT02224781
Conditions: BRAF NP_004324.2:p.V600X; Metastatic Melanoma; Progressive Disease; Recurrent Melanoma; Stage III Cutaneous Melanoma AJCC v7; Stage IIIA Cutaneous Melanoma AJCC v7; Stage IIIB Cutaneous Melanoma AJCC v7; Stage IIIC Cutaneous Melanoma AJCC v7; Stage IV Cutaneous Melanoma AJCC v6 and v7; Unresectable Cutaneous Melanoma
Interventions: Drug: Dabrafenib; Drug: Dabrafenib Mesylate; Biological: Ipilimumab; Biological: Nivolumab; Other: Quality-of-Life Assessment; Drug: Trametinib; Drug: Trametinib Dimethyl Sulfoxide
Sponsor: National Cancer Institute (NCI)
Recruiting
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
NCT02201992
Conditions: ALK Gene Rearrangement; ALK Gene Translocation; ALK Positive; Stage IB Non-Small Cell Lung Carcinoma AJCC v7; Stage II Non-Small Cell Lung Cancer AJCC v7; Stage IIA Non-Small Cell Lung Carcinoma AJCC v7; Stage IIB Non-Small Cell Lung Carcinoma AJCC v7; Stage IIIA Non-Small Cell Lung Cancer AJCC v7
Interventions: Other: Clinical Observation; Drug: Crizotinib; Other: Laboratory Biomarker Analysis
Sponsors: ECOG-ACRIN Cancer Research Group; National Cancer Institute (NCI)
Recruiting
Genetic Testing in Screening Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
NCT02194738
Conditions: Lung Adenocarcinoma; Lung Large Cell Carcinoma; Stage IB Lung Non-Small Cell Carcinoma AJCC v7; Stage IB Lung Squamous Cell Carcinoma AJCC v7; Stage II Lung Non-Small Cell Cancer AJCC v7; Stage II Lung Squamous Cell Carcinoma AJCC v7; Stage IIA Lung Non-Small Cell Carcinoma AJCC v7; Stage IIA Lung Squamous Cell Carcinoma AJCC v7; Stage IIB Lung Non-Small Cell Carcinoma AJCC v7; Stage IIB Lung Squamous Cell Carcinoma AJCC v7; Stage IIIA Lung Non-Small Cell Cancer AJCC v7; Stage IIIA Lung Squamous Cell Carcinoma AJCC v7
Interventions: Other: Clinical Observation; Drug: Crizotinib; Other: Cytology Specimen Collection Procedure; Drug: Erlotinib Hydrochloride; Biological: Nivolumab; Other: Placebo
Sponsor: National Cancer Institute (NCI)
Recruiting
Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)
NCT02193282
Conditions: ALK Gene Rearrangement; EGFR Exon 19 Deletion Mutation; EGFR NP_005219.2:p.L858R; Stage IB Lung Non-Small Cell Carcinoma AJCC v7; Stage II Lung Non-Small Cell Cancer AJCC v7; Stage IIA Lung Non-Small Cell Carcinoma AJCC v7; Stage IIB Lung Non-Small Cell Carcinoma AJCC v7; Stage IIIA Lung Non-Small Cell Cancer AJCC v7
Interventions: Other: Clinical Observation; Drug: Erlotinib Hydrochloride; Other: Laboratory Biomarker Analysis; Other: Placebo
Sponsor: National Cancer Institute (NCI)
Recruiting
Pomalidomide and Dexamethasone With or Without Ixazomib in Treating Patients With Relapsed Multiple Myeloma
NCT02004275
Condition: Multiple Myeloma in Relapse
Interventions: Drug: pomalidomide; Drug: ixazomib; Drug: dexamethasone
Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI); Celgene Corporation; Millennium Pharmaceuticals, Inc.
Recruiting
Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.
NCT01996865
Condition: Lymphoma, Non-Hodgkin
Interventions: Drug: Lenalidomide; Drug: Rituximab
Sponsor: Celgene
Recruiting
A Safety Study of SGN-LIV1A in Breast Cancer Patients
NCT01969643
Condition: Breast Cancer
Interventions: Drug: SGN-LIV1A; Drug: Trastuzumab
Sponsor: Seattle Genetics, Inc.
Recruiting
Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy
NCT01901094
Conditions: Stage II Breast Cancer; Stage IIIA Breast Cancer
Interventions: Procedure: Axillary Lymph Node Dissection (ALND); Radiation: Nodal Radiation Therapy; Radiation: Axillary Radiation Therapy
Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI); Canadian Cancer Trials Group
Recruiting
Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
NCT01896999
Conditions: Recurrent Classic Hodgkin Lymphoma; Refractory Classic Hodgkin Lymphoma
Interventions: Drug: Brentuximab Vedotin; Biological: Ipilimumab; Biological: Nivolumab
Sponsor: National Cancer Institute (NCI)
Recruiting
A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)
NCT01848561
Condition: Ulcerative Colitis (UC)
Intervention:
Sponsor: AbbVie
Recruiting
MRI and Mammography Before Surgery in Patients With Stage I-II Breast Cancer
NCT01805076
Conditions: Estrogen Receptor-negative Breast Cancer; Progesterone Receptor-negative Breast Cancer; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage II Breast Cancer; Triple-negative Breast Cancer
Interventions: Procedure: Breast surgery; Procedure: Magnetic resonance imaging; Procedure: Mammography
Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI); American College of Radiology Imaging Network
Recruiting
Connect® MDS/AML Disease Registry
NCT01688011
Conditions: Myelodysplastic Syndromes; Acute Myeloid Leukemia
Intervention:
Sponsor: Celgene
Recruiting
Framing Eighteen Coils in Cerebral Aneurysms Trial
NCT01655784
Condition: Cerebral Aneurysm
Interventions: Procedure: Coil Embolization with larger Diameter Coils; Procedure: Coil Embolization with Standard Diameter Coils
Sponsors: Vanderbilt University Medical Center; Stryker Neurovascular
Recruiting
Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma
NCT00887146
Condition: Brain and Central Nervous System Tumors
Interventions: Drug: concomitant temozolomide (TMZ); Radiation: radiotherapy; Drug: procarbazine; Drug: adjuvant temozolomide (TMZ); Drug: CCNU; Drug: vincristine
Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI); European Organisation for Research and Treatment Center (EORTC); Canadian Cancer Trials Group
Recruiting
Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide
NCT00632853
Condition: Lung Cancer
Interventions: Radiation: Standard Radiation Dose Therapy; Drug: cisplatin; Drug: etoposide; Radiation: High Radiation Dose Therapy; Drug: carboplatin
Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI)
Recruiting
Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma
NCT03794349
Conditions: Ganglioneuroblastoma; Recurrent Neuroblastoma; Refractory Neuroblastoma
Interventions: Biological: Dinutuximab; Drug: Eflornithine; Drug: Irinotecan; Biological: Sargramostim; Drug: Temozolomide
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting
A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered-dose Inhaler (BDA MDI/PT027) in Adults and Children 4 Years of Age or Older With Asthma
NCT03769090
Condition: Asthma
Interventions: Combination Product: Budesonide/albuterol sulfate metered-dose inhaler 80/180 μg; Combination Product: Budesonide/albuterol sulfate metered-dose inhaler 160/180 μg; Combination Product: Albuterol sulfate metered-dose inhaler 180 μg
Sponsor: Bond Avillion 2 Development LP
Recruiting
Registry of Subjects With Drug Resistant Epilepsy and Treated With the VNS Therapy System.
NCT03529045
Conditions: Epilepsy; Seizures; Drug Resistant Epilepsy
Intervention: Device: Vagus Nerve Stimulation (VNS) Therapy
Sponsor: LivaNova
Recruiting
Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS)
NCT03493685
Condition: Focal Segmental Glomerulosclerosis
Interventions: Drug: sparsentan; Drug: irbesartan
Sponsor: Retrophin, Inc.
Recruiting
CHaractErizing CFTR Modulated Changes in Sweat Chloride and Their Association With Clinical Outcomes
NCT03350828
Condition: Cystic Fibrosis
Intervention:
Sponsors: Nicole Hamblett; Cystic Fibrosis Foundation
Recruiting
An Open-Label Study of Defibrotide for the Prevention of Acute Graft-versus-Host-Disease (AGvHD)
NCT03339297
Conditions: Graft-versus-host Disease; Acute-graft-versus-host Disease
Interventions: Drug: Defibrotide; Drug: Standard of Care
Sponsor: Jazz Pharmaceuticals
Recruiting
An Efficacy and Safety Study of SHP647 as Maintenance Therapy in Participants With Moderate to Severe Ulcerative Colitis
NCT03290781
Condition: Ulcerative Colitis
Interventions: Drug: SHP647; Other: Placebo
Sponsor: Shire
Recruiting
A Safety Extension Study of SHP647 in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)
NCT03283085
Conditions: Crohn's Disease; Ulcerative Colitis
Interventions: Drug: 25 mg SHP647; Drug: 75 mg SHP647
Sponsor: Shire
Recruiting
Efficacy and Safety Study of SHP647 as Induction Therapy in Participants With Moderate to Severe Ulcerative Colitis
NCT03259334
Condition: Ulcerative Colitis
Interventions: Drug: SHP647; Other: Placebo
Sponsor: Shire
Recruiting
A Study of AeroVanc for the Treatment of MRSA Infection in CF Patients
NCT03181932
Conditions: MRSA; Cystic Fibrosis
Interventions: Drug: Vancomycin inhalation powder; Drug: Placebo inhalation powder
Sponsor: Savara Inc.
Recruiting
A Study of the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Crohn's Disease
NCT03105128
Condition: Crohn's Disease
Interventions: Drug: placebo for risankizumab; Drug: risankizumab IV; Drug: risankizumab SC
Sponsor: AbbVie
Recruiting
A Study to Assess the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment
NCT03104413
Condition: Crohn's Disease
Interventions: Drug: placebo for risankizumab IV; Drug: risankizumab SC; Drug: risankizumab IV
Sponsor: AbbVie
Recruiting
A 5-year Longitudinal Observational Study of Patients With Nonalcoholic Fatty Liver (NAFL) or Nonalcoholic Steatohepatitis (NASH)
NCT02815891
Conditions: Nonalcoholic Fatty Liver; Nonalcoholic Steatohepatitis
Intervention:
Sponsor: Target PharmaSolutions, Inc.
Recruiting
A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors
NCT02576431
Condition: Solid Tumors Harboring NTRK Fusion
Intervention: Drug: BAY2757556 (Larotrectinib, Vitrakvi)
Sponsor: Bayer
Recruiting
A Comparison of Intra-operative Radiotherapy Boost With External Beam Radiotherapy Boost in Early Breast Cancer.
NCT01792726
Condition: Early Breast Cancer
Intervention: Radiation: Boost to the tumour bed
Sponsors: University College, London; National Institute for Health Research, United Kingdom
Recruiting
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
NCT01351545
Conditions: Hematologic Malignancies; Inherited Disorders of Metabolism; Inherited Abnormalities of Platelets; Histiocytic Disorders; Acute Myelogenous Leukemia (AML or ANLL); Acute Lymphoblastic Leukemia (ALL); Other Acute Leukemia; Chronic Myelogenous Leukemia (CML); Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases; Other Leukemia; Hodgkin Lymphoma; Non-hodgkin Lymphoma; Multiple Myeloma/ Plasma Cell Disorder (PCD); Inherited Abnormalities of Erythrocyte Differentiation or Function; Disorders of the Immune System; Automimmune Diseases; Severe Aplastic Anemia
Intervention: Drug: A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)
Sponsors: Center for International Blood and Marrow Transplant Research; National Marrow Donor Program
Recruiting
Neuropsychological and Behavioral Testing in Younger Patients With Cancer
NCT00772200
Conditions: Childhood Malignant Neoplasm; Cognitive Side Effects of Cancer Therapy
Interventions: Procedure: Cognitive Assessment; Other: Quality-of-Life Assessment
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting
Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer
NCT00492778
Conditions: Endometrial Adenocarcinoma; Endometrial Adenosquamous Carcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation; Endometrial Serous Adenocarcinoma; Recurrent Uterine Corpus Carcinoma
Interventions: Radiation: 3-Dimensional Conformal Radiation Therapy; Drug: Cisplatin; Radiation: Intensity-Modulated Radiation Therapy; Radiation: Internal Radiation Therapy
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting

Menu

Categories

Recent Listings

Post your clinical trial on JoinClinicalTrials.com

JoinClinicalTrials.com

Results

Post your clinical trial on JoinClinicalTrials.com

Popular Now